首页 > 最新文献

Journal of Research in Pharmacy Practice最新文献

英文 中文
The Effectiveness of Perovskia abrotanoides Extract Topical Formulation on the Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial. Perovskia abrotanoides 提取物外用制剂对皮肤利什曼病的疗效:随机对照临床试验。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-30 eCollection Date: 2023-07-01 DOI: 10.4103/jrpp.jrpp_13_24
Maryam Sadat Tayebi, Nazila Poostiyan, Masoud Sadeghi Dinani, Erfaneh Ghassami, Rasool Soltani

Objective: Despite many attempts to treat leishmaniasis, new approaches are necessary to reduce the burden of disease. Perovskia abrotanoides (Brazambel) has shown significant effects against Leishmania parasites in some studies. This study aimed to investigate the effects of P. abrotanoides extract topical formulation on cutaneous leishmaniasis.

Methods: In this randomized controlled clinical trial, patients with cutaneous leishmaniasis were assigned to experimental (n = 18) and control (n = 18) groups. Both groups received intralesional meglumine antimoniate (Glucantime®). The experimental group also received 5% Brazambel extract ointment once a day. The interventions continued until the complete healing of the lesions (reepithelialization) for a maximum of 8 weeks. The clinical response, defined as complete response (reepithelialization >75%), partial response (reepithelialization 50%-75%), or treatment failure (reepithelialization <50%), was compared between the groups.

Findings: The percentage of reepithelialization in the experimental group (4th week: 64.44 ± 25.13; 8th week: 83.85 ± 11.54) was higher than the control group (4th week: 53.97 ± 25.88; 8th week: 76.27 ± 21.67); however, the differences were not statistically significant (P = 0.252 and 0.494, respectively). Moreover, there was no significant difference between the experimental and control groups regarding the rate of complete healing (88.9% vs. 72.2%, respectively).

Conclusion: The use of P. abrotanoides extract 5% topical formulation does not affect the healing of cutaneous leishmaniasis.

目的:尽管已多次尝试治疗利什曼病,但仍需要新的方法来减轻疾病负担。在一些研究中,Perovskia abrotanoides(Brazambel)对利什曼病寄生虫有显著效果。本研究旨在探讨P. abrotanoides提取物外用制剂对皮肤利什曼病的影响:在这项随机对照临床试验中,皮肤利什曼病患者被分为实验组(18 人)和对照组(18 人)。实验组和对照组均接受鞘内注射甲硝唑抗锑酸盐(Glucantime®)。实验组还接受每天一次的 5% Brazambel 提取物软膏治疗。干预措施一直持续到皮损完全愈合(再上皮化),最多持续 8 周。临床反应的定义为完全反应(上皮再化>75%)、部分反应(上皮再化50%-75%)或治疗失败(上皮再化结果:实验组的再上皮化百分比(第 4 周:64.44 ± 25.13;第 8 周:83.85 ± 11.54)高于对照组(第 4 周:53.97 ± 25.88;第 8 周:76.27 ± 21.67),但差异无统计学意义(P = 0.252 和 0.494)。此外,实验组和对照组在完全愈合率方面没有明显差异(分别为 88.9% 对 72.2%):结论:使用阿布罗塔诺苷提取物 5%局部制剂不会影响皮肤利什曼病的愈合。
{"title":"The Effectiveness of <i>Perovskia abrotanoides</i> Extract Topical Formulation on the Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial.","authors":"Maryam Sadat Tayebi, Nazila Poostiyan, Masoud Sadeghi Dinani, Erfaneh Ghassami, Rasool Soltani","doi":"10.4103/jrpp.jrpp_13_24","DOIUrl":"10.4103/jrpp.jrpp_13_24","url":null,"abstract":"<p><strong>Objective: </strong>Despite many attempts to treat leishmaniasis, new approaches are necessary to reduce the burden of disease. <i>Perovskia abrotanoides</i> (Brazambel) has shown significant effects against <i>Leishmania</i> parasites in some studies. This study aimed to investigate the effects of <i>P. abrotanoides</i> extract topical formulation on cutaneous leishmaniasis.</p><p><strong>Methods: </strong>In this randomized controlled clinical trial, patients with cutaneous leishmaniasis were assigned to experimental (<i>n</i> = 18) and control (<i>n</i> = 18) groups. Both groups received intralesional meglumine antimoniate (Glucantime<sup>®</sup>). The experimental group also received 5% Brazambel extract ointment once a day. The interventions continued until the complete healing of the lesions (reepithelialization) for a maximum of 8 weeks. The clinical response, defined as complete response (reepithelialization >75%), partial response (reepithelialization 50%-75%), or treatment failure (reepithelialization <50%), was compared between the groups.</p><p><strong>Findings: </strong>The percentage of reepithelialization in the experimental group (4<sup>th</sup> week: 64.44 ± 25.13; 8<sup>th</sup> week: 83.85 ± 11.54) was higher than the control group (4<sup>th</sup> week: 53.97 ± 25.88; 8<sup>th</sup> week: 76.27 ± 21.67); however, the differences were not statistically significant (<i>P</i> = 0.252 and 0.494, respectively). Moreover, there was no significant difference between the experimental and control groups regarding the rate of complete healing (88.9% vs. 72.2%, respectively).</p><p><strong>Conclusion: </strong>The use of <i>P. abrotanoides</i> extract 5% topical formulation does not affect the healing of cutaneous leishmaniasis.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"12 3","pages":"104-109"},"PeriodicalIF":1.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of an Oral Solution Containing Five Herbal Extracts in the Treatment of Urolithiasis: A Randomized, Single-blind, Placebo-controlled Clinical Trial. 含五种草药提取物的口服溶液治疗尿路结石的疗效:随机、单盲、安慰剂对照临床试验。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-30 eCollection Date: 2023-07-01 DOI: 10.4103/jrpp.jrpp_11_24
Sahand Samandarian, Rasool Soltani, Valiollah Hajhashemi, Mehdi Dehghani, Mohammad Matinfar, Mohaddese Mahboubi, Afsaneh Mohsenzadeh

Objective: The high prevalence of urolithiasis and its recurrence entail the preparation of an efficient drug with the least side effects. Tribulus terrestris, Urtica dioica, Adiantum capillus-veneris, Stigma maydis (corn silk), and Cucumis melo are herbal remedies utilized in traditional medicine for urolithiasis. This study aimed to assess the efficiency of these plants' extracts in treating urolithiasis.

Methods: In a randomized, single-blind, placebo-controlled clinical trial, participants meeting inclusion criteria were randomly allocated to the drug (n = 27) and placebo (n = 27) groups to take herbal or placebo solutions, respectively, at a dose of 60 drops 3 times daily for 4 weeks with standard treatment. Before and after the intervention, 24-h urine volume and the quantities of calcium, sodium, citrate, oxalate, urea, creatinine, and uric acid in 24-h urine, and urinary pH were measured. The number and size (diameter in mm) of stones were determined by ultrasonography and recorded for each patient.

Findings: Except for 24 h urine volume, other urinary parameters did not alter significantly at the end of the intervention compared to baseline. Furthermore, the two groups had no significant difference regarding these indices. Regarding stone parameters, the stone size decreased significantly in the drug group compared to the placebo group (P = 0.049). The number of cases with complete stone expulsion in the drug group was significantly higher than in the placebo group (12 cases vs. 4 cases, respectively, P = 0.017).

Conclusion: Oral consumption of the herbal solution causes stone size reduction and stone expulsion in patients with urolithiasis.

目的:泌尿系统结石的发病率高且易复发,因此需要制备一种副作用最小的高效药物。在传统医学中,刺蒺藜、荨麻、茵陈、玉米须和瓜果是治疗尿路结石的草药。本研究旨在评估这些植物提取物治疗尿路结石的效果:在一项随机、单盲、安慰剂对照临床试验中,符合纳入标准的参与者被随机分配到药物组(n = 27)和安慰剂组(n = 27),分别服用草药或安慰剂溶液,剂量为每日 3 次,每次 60 滴,持续 4 周,同时接受标准治疗。干预前后,测量了 24 小时尿量、24 小时尿液中钙、钠、柠檬酸盐、草酸盐、尿素、肌酐和尿酸的含量以及尿液 pH 值。通过超声波检查确定结石的数量和大小(直径为毫米),并记录每位患者的检查结果:结果:除 24 小时尿量外,干预结束时其他尿液参数与基线相比没有明显变化。此外,两组患者在这些指标上也没有明显差异。在结石参数方面,与安慰剂组相比,药物组的结石体积明显缩小(P = 0.049)。药物组完全排出结石的病例数明显高于安慰剂组(分别为 12 例和 4 例,P = 0.017):结论:口服草药溶液可使泌尿系统结石患者的结石缩小并排出。
{"title":"Efficacy of an Oral Solution Containing Five Herbal Extracts in the Treatment of Urolithiasis: A Randomized, Single-blind, Placebo-controlled Clinical Trial.","authors":"Sahand Samandarian, Rasool Soltani, Valiollah Hajhashemi, Mehdi Dehghani, Mohammad Matinfar, Mohaddese Mahboubi, Afsaneh Mohsenzadeh","doi":"10.4103/jrpp.jrpp_11_24","DOIUrl":"10.4103/jrpp.jrpp_11_24","url":null,"abstract":"<p><strong>Objective: </strong>The high prevalence of urolithiasis and its recurrence entail the preparation of an efficient drug with the least side effects. <i>Tribulus terrestris</i>, <i>Urtica dioica</i>, <i>Adiantum capillus-veneris</i>, <i>Stigma maydis</i> (corn silk), and <i>Cucumis melo</i> are herbal remedies utilized in traditional medicine for urolithiasis. This study aimed to assess the efficiency of these plants' extracts in treating urolithiasis.</p><p><strong>Methods: </strong>In a randomized, single-blind, placebo-controlled clinical trial, participants meeting inclusion criteria were randomly allocated to the drug (<i>n</i> = 27) and placebo (<i>n</i> = 27) groups to take herbal or placebo solutions, respectively, at a dose of 60 drops 3 times daily for 4 weeks with standard treatment. Before and after the intervention, 24-h urine volume and the quantities of calcium, sodium, citrate, oxalate, urea, creatinine, and uric acid in 24-h urine, and urinary pH were measured. The number and size (diameter in mm) of stones were determined by ultrasonography and recorded for each patient.</p><p><strong>Findings: </strong>Except for 24 h urine volume, other urinary parameters did not alter significantly at the end of the intervention compared to baseline. Furthermore, the two groups had no significant difference regarding these indices. Regarding stone parameters, the stone size decreased significantly in the drug group compared to the placebo group (<i>P</i> = 0.049). The number of cases with complete stone expulsion in the drug group was significantly higher than in the placebo group (12 cases vs. 4 cases, respectively, <i>P</i> = 0.017).</p><p><strong>Conclusion: </strong>Oral consumption of the herbal solution causes stone size reduction and stone expulsion in patients with urolithiasis.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"12 3","pages":"96-103"},"PeriodicalIF":1.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Stem Cell Mobilization and CD34+ Cell Collection in a Poor Mobilizer: A Case Report Utilizing a Combination of Recombinant Growth Colony Stimulating Factor, Recombinant Human Growth Factor, and Plerixafor. 干细胞动员能力差者成功动员并采集 CD34+ 细胞:联合使用重组生长集落刺激因子、重组人生长因子和普乐沙福的病例报告。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-30 eCollection Date: 2023-07-01 DOI: 10.4103/jrpp.jrpp_46_23
Maliheh Kazemi Najafabadi, Azadeh Moghaddas, Mozhgan Karimifar, Ali Darakhshandeh

Diffuse large B-cell lymphoma is the most prevalent form of non-Hodgkin's lymphoma that is usually treated with chemoimmunotherapy. If the disease proves refractory or recurrent, the primary treatment approach involves high-dose chemotherapy with bone marrow transplantation. The collection of peripheral blood stem cells before transplantation plays a vital role in the treatment process, necessitating the mobilization of blood stem cells from the bone marrow to the peripheral blood. Despite using standard methods such as granulocyte colony-stimulating factor (G-CSF), chemotherapy, and plerixafor, some patients cannot collect an optimal count of CD34+ cells for transplantation. Managing these patients with poor mobilization poses significant challenges. In this article, we present a case of a poor mobilizer patient who achieved prosperous mobilization by using recombinant human G-CSF, recombinant human growth hormone, and plerixafor.

弥漫大B细胞淋巴瘤是非霍奇金淋巴瘤中最常见的一种,通常采用化学免疫疗法进行治疗。如果病情难治或复发,主要治疗方法包括大剂量化疗和骨髓移植。移植前的外周血干细胞采集在治疗过程中起着至关重要的作用,必须将骨髓中的造血干细胞动员到外周血中。尽管使用了粒细胞集落刺激因子(G-CSF)、化疗和普利沙佛等标准方法,一些患者仍无法为移植收集到最佳数量的CD34+细胞。如何管理这些动员能力差的患者是一项重大挑战。在本文中,我们介绍了一例动员能力差的患者,该患者通过使用重组人G-CSF、重组人生长激素和普乐沙福实现了良好的动员。
{"title":"Successful Stem Cell Mobilization and CD34+ Cell Collection in a Poor Mobilizer: A Case Report Utilizing a Combination of Recombinant Growth Colony Stimulating Factor, Recombinant Human Growth Factor, and Plerixafor.","authors":"Maliheh Kazemi Najafabadi, Azadeh Moghaddas, Mozhgan Karimifar, Ali Darakhshandeh","doi":"10.4103/jrpp.jrpp_46_23","DOIUrl":"10.4103/jrpp.jrpp_46_23","url":null,"abstract":"<p><p>Diffuse large B-cell lymphoma is the most prevalent form of non-Hodgkin's lymphoma that is usually treated with chemoimmunotherapy. If the disease proves refractory or recurrent, the primary treatment approach involves high-dose chemotherapy with bone marrow transplantation. The collection of peripheral blood stem cells before transplantation plays a vital role in the treatment process, necessitating the mobilization of blood stem cells from the bone marrow to the peripheral blood. Despite using standard methods such as granulocyte colony-stimulating factor (G-CSF), chemotherapy, and plerixafor, some patients cannot collect an optimal count of CD34+ cells for transplantation. Managing these patients with poor mobilization poses significant challenges. In this article, we present a case of a poor mobilizer patient who achieved prosperous mobilization by using recombinant human G-CSF, recombinant human growth hormone, and plerixafor.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"12 3","pages":"110-113"},"PeriodicalIF":1.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Follow-up of Methanol-related Visual Defects in a Cohort Study: Initial Severity Predicts Long-term Outcome. 一项队列研究中甲醇相关视力缺陷的随访:最初的严重程度可预测长期结果。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-30 eCollection Date: 2023-07-01 DOI: 10.4103/jrpp.jrpp_80_22
Farzad Gheshlaghi, Anselm Wong, Rezvan Firuzfar, Keyvan Jenab, Shayan Gheshlaghi, Golnoosh Shahverdi, Nastaran Eizadi-Mood

Objective: Methanol poisoning can occur either intentionally through the consumption of methanol-containing products or accidentally through ingestion, resulting in visual impairment. We assessed the long-term visual sequelae in patients with methanol poisoning.

Methods: This prospective cohort study was conducted at referral centers, Khorshid and Alzahra University Hospitals, affiliated with Isfahan University of Medical Sciences, Isfahan, Iran. The study included patients hospitalized for methanol poisoning from June 22, 2018, to June 21, 2020, with follow-up extended until June 2021. Toxico-clinical and ophthalmologic examination data were collected from patients upon hospital admission, discharge, and during follow-up.

Findings: Thirty-nine patients were assessed in this study. The majority of them (94.9%) were male, with an average age of 34 years. Patients who presented with reduced visual acuity (VA) upon admission subsequently showed abnormalities (in acuity and visual fields) during follow-up (n = 13). Among the patients who displayed visual field defects on admission, bilateral optic disc atrophy was observed in follow-up (n = 13). Conversely, patients who reported blurred vision, with or without photophobia upon admission, had normal results in their follow-up eye examinations. Among the 36 patients who underwent dialysis, 14 (38.9%) exhibited visual impairment during follow-up examinations. Additionally, 38 patients received sodium bicarbonate, and 14 of them (36.85%) also presented ocular abnormalities.

Conclusion: Patients who demonstrated VA deficits upon admission are more likely to experience long-term VA and visual field defects, as well as optic disc atrophy. Patients who solely complained of blurred vision, with or without photophobia, during admission were less likely to develop long-term visual defects.

目的:甲醇中毒可因有意食用含甲醇的产品或意外摄入而导致视力受损。我们对甲醇中毒患者的长期视觉后遗症进行了评估:这项前瞻性队列研究在伊朗伊斯法罕市伊斯法罕医科大学附属霍尔希德和阿尔扎赫拉大学医院转诊中心进行。研究对象包括 2018 年 6 月 22 日至 2020 年 6 月 21 日期间因甲醇中毒住院的患者,随访期延长至 2021 年 6 月。研究收集了患者入院、出院和随访期间的毒物临床和眼科检查数据:本研究评估了 39 名患者。其中大部分(94.9%)为男性,平均年龄为 34 岁。入院时视力(VA)下降的患者在随访期间出现视力和视野异常(13 人)。在入院时出现视野缺损的患者中,随访期间观察到双侧视盘萎缩(13 人)。相反,入院时报告视力模糊并伴有或不伴有畏光的患者,其后续眼科检查结果均正常。在接受透析的 36 名患者中,有 14 人(38.9%)在随访检查中出现视力障碍。此外,38 名患者接受了碳酸氢钠治疗,其中 14 人(36.85%)也出现了眼部异常:结论:入院时出现视力障碍的患者更有可能出现长期视力和视野缺损以及视盘萎缩。入院时仅主诉视力模糊、伴有或不伴有畏光的患者出现长期视力缺陷的可能性较小。
{"title":"Follow-up of Methanol-related Visual Defects in a Cohort Study: Initial Severity Predicts Long-term Outcome.","authors":"Farzad Gheshlaghi, Anselm Wong, Rezvan Firuzfar, Keyvan Jenab, Shayan Gheshlaghi, Golnoosh Shahverdi, Nastaran Eizadi-Mood","doi":"10.4103/jrpp.jrpp_80_22","DOIUrl":"10.4103/jrpp.jrpp_80_22","url":null,"abstract":"<p><strong>Objective: </strong>Methanol poisoning can occur either intentionally through the consumption of methanol-containing products or accidentally through ingestion, resulting in visual impairment. We assessed the long-term visual sequelae in patients with methanol poisoning.</p><p><strong>Methods: </strong>This prospective cohort study was conducted at referral centers, Khorshid and Alzahra University Hospitals, affiliated with Isfahan University of Medical Sciences, Isfahan, Iran. The study included patients hospitalized for methanol poisoning from June 22, 2018, to June 21, 2020, with follow-up extended until June 2021. Toxico-clinical and ophthalmologic examination data were collected from patients upon hospital admission, discharge, and during follow-up.</p><p><strong>Findings: </strong>Thirty-nine patients were assessed in this study. The majority of them (94.9%) were male, with an average age of 34 years. Patients who presented with reduced visual acuity (VA) upon admission subsequently showed abnormalities (in acuity and visual fields) during follow-up (<i>n</i> = 13). Among the patients who displayed visual field defects on admission, bilateral optic disc atrophy was observed in follow-up (<i>n</i> = 13). Conversely, patients who reported blurred vision, with or without photophobia upon admission, had normal results in their follow-up eye examinations. Among the 36 patients who underwent dialysis, 14 (38.9%) exhibited visual impairment during follow-up examinations. Additionally, 38 patients received sodium bicarbonate, and 14 of them (36.85%) also presented ocular abnormalities.</p><p><strong>Conclusion: </strong>Patients who demonstrated VA deficits upon admission are more likely to experience long-term VA and visual field defects, as well as optic disc atrophy. Patients who solely complained of blurred vision, with or without photophobia, during admission were less likely to develop long-term visual defects.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"12 3","pages":"88-95"},"PeriodicalIF":1.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypoglycemic Agents and Anesthetic Techniques to Ameliorate Stress Hyperglycemia in Critically Ill Patients: A Systematic Review. 缓解重症患者应激性高血糖的降糖药物和麻醉技术:系统回顾。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-30 eCollection Date: 2023-07-01 DOI: 10.4103/jrpp.jrpp_45_23
Fatemeh Rahimpour, Malihe Nejati, Azadeh Moghaddas, Shadi Farsaei, Awat Feizi

The concurrent utilization of hypoglycemic agents and anesthetic techniques has been demonstrated to mitigate stress hyperglycemia in critically ill patients without diabetes, thereby contributing to enhanced patient outcomes. Stress hyperglycemia, characterized by elevated blood glucose levels as a result of acute illness or physiological stress, frequently manifests in patients experiencing critical illness. This condition has been linked to augmented morbidity, protracted hospitalization durations, and elevated mortality rates. This review aims to introduce and critically assess various hypoglycemic agents and anesthetic techniques employed to alleviate stress hyperglycemia, emphasizing the necessity for continued research to comprehensively ascertain the safety and efficacy of these approaches, which will facilitate their broader integration.

事实证明,同时使用降糖药和麻醉技术可减轻没有糖尿病的危重病人的应激性高血糖,从而改善病人的预后。应激性高血糖的特点是因急性疾病或生理应激导致血糖水平升高,经常在危重病人中出现。这种情况与发病率增加、住院时间延长和死亡率升高有关。本综述旨在介绍和批判性评估用于缓解应激性高血糖的各种降糖药物和麻醉技术,强调有必要继续开展研究,以全面确定这些方法的安全性和有效性,从而促进其更广泛的整合。
{"title":"Hypoglycemic Agents and Anesthetic Techniques to Ameliorate Stress Hyperglycemia in Critically Ill Patients: A Systematic Review.","authors":"Fatemeh Rahimpour, Malihe Nejati, Azadeh Moghaddas, Shadi Farsaei, Awat Feizi","doi":"10.4103/jrpp.jrpp_45_23","DOIUrl":"10.4103/jrpp.jrpp_45_23","url":null,"abstract":"<p><p>The concurrent utilization of hypoglycemic agents and anesthetic techniques has been demonstrated to mitigate stress hyperglycemia in critically ill patients without diabetes, thereby contributing to enhanced patient outcomes. Stress hyperglycemia, characterized by elevated blood glucose levels as a result of acute illness or physiological stress, frequently manifests in patients experiencing critical illness. This condition has been linked to augmented morbidity, protracted hospitalization durations, and elevated mortality rates. This review aims to introduce and critically assess various hypoglycemic agents and anesthetic techniques employed to alleviate stress hyperglycemia, emphasizing the necessity for continued research to comprehensively ascertain the safety and efficacy of these approaches, which will facilitate their broader integration.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"12 3","pages":"69-87"},"PeriodicalIF":1.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Artificial Intelligence in Anesthesia: Revolutionizing Patient Safety and Care. 人工智能在麻醉中的作用:革新患者安全和护理。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-31 eCollection Date: 2023-04-01 DOI: 10.4103/jrpp.jrpp_50_23
Ram Kumar Garg
{"title":"Role of Artificial Intelligence in Anesthesia: Revolutionizing Patient Safety and Care.","authors":"Ram Kumar Garg","doi":"10.4103/jrpp.jrpp_50_23","DOIUrl":"10.4103/jrpp.jrpp_50_23","url":null,"abstract":"","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"12 2","pages":"68"},"PeriodicalIF":1.0,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing Sequential Organ Failure Assessment Score, Acute Physiology and Chronic Health Evaluation II, Modified Acute Physiology and Chronic Health Evaluation II, Simplified Acute Physiology Score II and Poisoning Severity Score for Outcome Prediction of Pesticide Poisoned Patients Admitted to the Intensive Care Unit. 比较顺序器官衰竭评估评分、急性生理学和慢性健康评估 II、改良急性生理学和慢性健康评估 II、简化急性生理学评分 II 和中毒严重程度评分,以预测入住重症监护室的农药中毒患者的预后。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-31 eCollection Date: 2023-04-01 DOI: 10.4103/jrpp.jrpp_43_23
Gholamali Dorooshi, Shiva Samsamshariat, Farzad Gheshlaghi, Shafeajafar Zoofaghari, Akbar Hasanzadeh, Saeed Abbasi, Nastaran Eizadi-Mood

Objective: This study aimed to assess the severity of poisoning, various scoring systems, including Sequential Organ Failure Assessment (SOFA) score, acute physiology and chronic health evaluation II (APACHE II), Simplified Acute Physiology Score (SAPS II), Modified APACHE II, and poisoning severity score (PSS) were used. In this study, we compared the predictive value of these scoring systems on the outcome of pesticide-poisoned patients.

Methods: This is a cross-sectional study of pesticide-poisoned patients (140 patients) who were admitted to the intensive care unit (ICU) of Khorshid Hospital, Isfahan, Iran, between January 2015 and 2019. The area under the receiver operating characteristic (AUC) curve and the predictive value of scoring systems were compared.

Findings: Poisoning was higher in the male population (72.8%). The causes of poisoning were paraquat, (38.6%), aluminum phosphide, (32.1%), and organophosphate, (29.3%). The mean age of the patients was 33.9 years. Most patients (79.3%) attempted suicide. The mortality rate was 46.43%. The mean of "SOFA score," "APACHE II," "SAPS II," "Modified APACHE II," and "PSS" was 5.9; 15.7; 30.02; 15.8; and 1.9, respectively. There was a significant difference in the mean of all scoring systems for outcome prediction. Among all scoring systems, the SAPS II score with the cutoff point (16.5) had the best criteria for outcome prediction (AUC (0.831 ± 0.037), sensitivity (83.1%, 95% confidence interval [CI]: [71.7-91.2]), specificity (75.7%, 95% CI: [64.3-84.9]), positive predictive values (75.0%, 95% CI: [66.4-82.0]), negative predictive values (83.6%, 95% CI: [74.5-89.9]).

Conclusion: The SAPS II scoring system may be a suitable indicator for outcome predictions in pesticide-poisoned patients in the ICU.

研究目的本研究旨在评估中毒的严重程度,使用了多种评分系统,包括序贯器官衰竭评估(SOFA)评分、急性生理学和慢性健康评估 II(APACHE II)、简化急性生理学评分(SAPS II)、改良 APACHE II 和中毒严重程度评分(PSS)。在本研究中,我们比较了这些评分系统对农药中毒患者预后的预测价值:这是一项横断面研究,研究对象为 2015 年 1 月至 2019 年期间入住伊朗伊斯法罕 Khorshid 医院重症监护室(ICU)的农药中毒患者(140 名)。比较了接受者操作特征曲线下面积(AUC)和评分系统的预测价值:男性中毒率较高(72.8%)。中毒原因为百草枯(38.6%)、磷化铝(32.1%)和有机磷(29.3%)。患者的平均年龄为 33.9 岁。大多数患者(79.3%)试图自杀。死亡率为 46.43%。SOFA 评分"、"APACHE II"、"SAPS II"、"改良 APACHE II "和 "PSS "的平均值分别为 5.9、15.7、30.02、15.8 和 1.9。所有评分系统对结果预测的平均值均有明显差异。在所有评分系统中,以 16.5 为分界点的 SAPS II 评分具有最佳的结果预测标准(AUC(0.831 ± 0.037)、灵敏度(83.1%,95% 置信区间 [CI]:[71.7-91.2])、特异性(75.7%,95% CI:[64.3-84.9])、阳性预测值(75.0%,95% CI:[66.4-82.0])、阴性预测值(83.6%,95% CI:[74.5-89.9]):SAPSⅡ评分系统可能是预测重症监护室农药中毒患者预后的合适指标。
{"title":"Comparing Sequential Organ Failure Assessment Score, Acute Physiology and Chronic Health Evaluation II, Modified Acute Physiology and Chronic Health Evaluation II, Simplified Acute Physiology Score II and Poisoning Severity Score for Outcome Prediction of Pesticide Poisoned Patients Admitted to the Intensive Care Unit.","authors":"Gholamali Dorooshi, Shiva Samsamshariat, Farzad Gheshlaghi, Shafeajafar Zoofaghari, Akbar Hasanzadeh, Saeed Abbasi, Nastaran Eizadi-Mood","doi":"10.4103/jrpp.jrpp_43_23","DOIUrl":"10.4103/jrpp.jrpp_43_23","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the severity of poisoning, various scoring systems, including Sequential Organ Failure Assessment (SOFA) score, acute physiology and chronic health evaluation II (APACHE II), Simplified Acute Physiology Score (SAPS II), Modified APACHE II, and poisoning severity score (PSS) were used. In this study, we compared the predictive value of these scoring systems on the outcome of pesticide-poisoned patients.</p><p><strong>Methods: </strong>This is a cross-sectional study of pesticide-poisoned patients (140 patients) who were admitted to the intensive care unit (ICU) of Khorshid Hospital, Isfahan, Iran, between January 2015 and 2019. The area under the receiver operating characteristic (AUC) curve and the predictive value of scoring systems were compared.</p><p><strong>Findings: </strong>Poisoning was higher in the male population (72.8%). The causes of poisoning were paraquat, (38.6%), aluminum phosphide, (32.1%), and organophosphate, (29.3%). The mean age of the patients was 33.9 years. Most patients (79.3%) attempted suicide. The mortality rate was 46.43%. The mean of \"SOFA score,\" \"APACHE II,\" \"SAPS II,\" \"Modified APACHE II,\" and \"PSS\" was 5.9; 15.7; 30.02; 15.8; and 1.9, respectively. There was a significant difference in the mean of all scoring systems for outcome prediction. Among all scoring systems, the SAPS II score with the cutoff point (16.5) had the best criteria for outcome prediction (AUC (0.831 ± 0.037), sensitivity (83.1%, 95% confidence interval [CI]: [71.7-91.2]), specificity (75.7%, 95% CI: [64.3-84.9]), positive predictive values (75.0%, 95% CI: [66.4-82.0]), negative predictive values (83.6%, 95% CI: [74.5-89.9]).</p><p><strong>Conclusion: </strong>The SAPS II scoring system may be a suitable indicator for outcome predictions in pesticide-poisoned patients in the ICU.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"12 2","pages":"49-57"},"PeriodicalIF":1.0,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance Challenges in a Newly Established Clean Room at Omid Hospital, Isfahan, Iran: A Descriptive Study. 伊朗伊斯法罕市奥米德医院新建洁净室面临的性能挑战:描述性研究。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-31 eCollection Date: 2023-04-01 DOI: 10.4103/jrpp.jrpp_40_23
Mehrnaz Vaez, Mehran Sharifi, Sahar Karimi, Azadeh Moghaddas

Objective: This study aimed to comprehensively assess the challenges faced by a newly established clean room in the oncology center of Omid Hospital, Isfahan, Iran, one of the first of its kind in the country. The research also sought to identify the underlying causes of these challenges and propose potential solutions to address them.

Methods: A 6-month cross-sectional study was conducted from December 2021 to May 2022. International guidelines such as British Columbia Cancer Agencies' guideline of hazardous drugs, the National Institute for Occupational Safety and Health guideline for working with hazardous drugs, and United States pharmacopeia related to cleanroom performance were studied, translated, and summarized into a checklist. The staff performance in Omid Hospital's clean room was compared to the data collection form, and all medication errors were documented and analyzed. The study also explained the underlying causes of these challenges and proposed potential solutions.

Findings: Among 1005 chemotherapy regimens, 836 errors were detected, stemming from issues such as engineering and construction challenges, lack of human resources and essential equipment, and budgetary constraints.

Conclusion: Despite the involvement of a trained oncology clinical pharmacist, Omid Hospital's cleanroom faces significant challenges within the medical and hospital system, leading to non-standard challenges. The study recommends multidisciplinary approaches in the hospital to mitigate these challenges and improve cleanroom performance.

研究目的本研究旨在全面评估伊朗伊斯法罕市奥米德医院肿瘤中心新建立的洁净室所面临的挑战。研究还试图找出这些挑战的根本原因,并提出潜在的解决方法:从 2021 年 12 月到 2022 年 5 月进行了为期 6 个月的横断面研究。对不列颠哥伦比亚省癌症机构的危险药品指南、美国国家职业安全与健康研究所的危险药品工作指南以及美国药典等与洁净室性能相关的国际指南进行了研究、翻译,并总结成一份检查表。将奥米德医院洁净室工作人员的表现与数据收集表进行了比较,并记录和分析了所有用药错误。研究还解释了这些挑战的根本原因,并提出了潜在的解决方案:在 1005 个化疗方案中,发现了 836 个错误,原因包括工程和建筑方面的挑战、缺乏人力资源和必要设备以及预算限制等:尽管有训练有素的肿瘤临床药剂师参与,但奥米德医院的洁净室在医疗和医院系统中仍面临重大挑战,导致了非标准的难题。研究建议医院采用多学科方法来减轻这些挑战,提高洁净室的性能。
{"title":"Performance Challenges in a Newly Established Clean Room at Omid Hospital, Isfahan, Iran: A Descriptive Study.","authors":"Mehrnaz Vaez, Mehran Sharifi, Sahar Karimi, Azadeh Moghaddas","doi":"10.4103/jrpp.jrpp_40_23","DOIUrl":"10.4103/jrpp.jrpp_40_23","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to comprehensively assess the challenges faced by a newly established clean room in the oncology center of Omid Hospital, Isfahan, Iran, one of the first of its kind in the country. The research also sought to identify the underlying causes of these challenges and propose potential solutions to address them.</p><p><strong>Methods: </strong>A 6-month cross-sectional study was conducted from December 2021 to May 2022. International guidelines such as British Columbia Cancer Agencies' guideline of hazardous drugs, the National Institute for Occupational Safety and Health guideline for working with hazardous drugs, and United States pharmacopeia related to cleanroom performance were studied, translated, and summarized into a checklist. The staff performance in Omid Hospital's clean room was compared to the data collection form, and all medication errors were documented and analyzed. The study also explained the underlying causes of these challenges and proposed potential solutions.</p><p><strong>Findings: </strong>Among 1005 chemotherapy regimens, 836 errors were detected, stemming from issues such as engineering and construction challenges, lack of human resources and essential equipment, and budgetary constraints.</p><p><strong>Conclusion: </strong>Despite the involvement of a trained oncology clinical pharmacist, Omid Hospital's cleanroom faces significant challenges within the medical and hospital system, leading to non-standard challenges. The study recommends multidisciplinary approaches in the hospital to mitigate these challenges and improve cleanroom performance.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"12 2","pages":"33-43"},"PeriodicalIF":1.0,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of an Herbal Preparation (Atomy's HemoHIM®) against Ventilator-associated Pneumonia: A Randomized Controlled Clinical Trial. 草药制剂(Atomy's HemoHIM®)对呼吸机相关肺炎的疗效:随机对照临床试验。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-31 eCollection Date: 2023-04-01 DOI: 10.4103/jrpp.jrpp_9_23
Ghazal Khamooshpour, Hossein Mahjubipour, Shadi Farsaei

Objective: Despite the standard guideline recommendations to prevent ventilator-associated pneumonia (VAP), it has remained one of the common lung infections in the intensive care unit (ICU). This clinical trial was designed to evaluate the effect of HemoHIM®, a mixture of traditional Korean medicinal plants, on preventing VAP in ICU patients.

Methods: This randomized controlled clinical trial was conducted on mechanically ventilated adult ICU patients with a clinical pulmonary infection score of VAP ≤6 in the first 48 h of ventilation. Patients in the intervention group received a packet of HemoHIM daily and orally for 7 days in addition to standard prevention strategies. However, in the control group, only standard prevention strategies were carried out. All patients were followed daily for VAP incidence for 14 days.

Findings: The overall VAP incidence was 36.4 and 57.4 episodes per 1000 days of mechanical ventilation in the intervention and control groups, respectively (P = 0.041; odds ratio = 0.26; 95% confidence interval = 0.070-0.944). The median length of mechanical ventilation during study follow-up was significantly lower in the intervention than in the control group (P = 0.033). The number of pneumonia-free days during the study was considerably higher in the intervention group (P value of the log-rank test = 0.023).

Conclusion: According to the results of this study, the HemoHIM herbal supplement had beneficial effects in preventing the occurrence of VAP and significantly reduced the incidence of pneumonia in the intervention group. Further comprehensive research is required to draw more accurate conclusions.

目的:尽管标准指南建议预防呼吸机相关肺炎(VAP),但它仍然是重症监护病房(ICU)中常见的肺部感染之一。本临床试验旨在评估 HemoHIM®(一种韩国传统药用植物的混合物)对 ICU 患者预防 VAP 的效果:这项随机对照临床试验的对象是通气 48 小时内 VAP 临床肺部感染评分≤6 分的成人 ICU 机械通气患者。除标准预防策略外,干预组患者每天口服一包 HemoHIM,连续服用 7 天。而在对照组中,只实施了标准预防策略。对所有患者进行为期 14 天的 VAP 发生率每日随访:干预组和对照组的 VAP 总发生率分别为每 1000 天机械通气 36.4 次和 57.4 次(P = 0.041;几率比 = 0.26;95% 置信区间 = 0.070-0.944)。研究随访期间,干预组的机械通气时间中位数明显低于对照组(P = 0.033)。干预组研究期间无肺炎天数明显高于对照组(对数秩检验的 P 值 = 0.023):根据本研究的结果,HemoHIM 中药补充剂对预防 VAP 的发生有益处,并显著降低了干预组的肺炎发病率。要得出更准确的结论,还需要进一步的综合研究。
{"title":"Efficacy of an Herbal Preparation (Atomy's HemoHIM<sup>®</sup>) against Ventilator-associated Pneumonia: A Randomized Controlled Clinical Trial.","authors":"Ghazal Khamooshpour, Hossein Mahjubipour, Shadi Farsaei","doi":"10.4103/jrpp.jrpp_9_23","DOIUrl":"10.4103/jrpp.jrpp_9_23","url":null,"abstract":"<p><strong>Objective: </strong>Despite the standard guideline recommendations to prevent ventilator-associated pneumonia (VAP), it has remained one of the common lung infections in the intensive care unit (ICU). This clinical trial was designed to evaluate the effect of HemoHIM<sup>®</sup>, a mixture of traditional Korean medicinal plants, on preventing VAP in ICU patients.</p><p><strong>Methods: </strong>This randomized controlled clinical trial was conducted on mechanically ventilated adult ICU patients with a clinical pulmonary infection score of VAP ≤6 in the first 48 h of ventilation. Patients in the intervention group received a packet of HemoHIM daily and orally for 7 days in addition to standard prevention strategies. However, in the control group, only standard prevention strategies were carried out. All patients were followed daily for VAP incidence for 14 days.</p><p><strong>Findings: </strong>The overall VAP incidence was 36.4 and 57.4 episodes per 1000 days of mechanical ventilation in the intervention and control groups, respectively (<i>P</i> = 0.041; odds ratio = 0.26; 95% confidence interval = 0.070-0.944). The median length of mechanical ventilation during study follow-up was significantly lower in the intervention than in the control group (<i>P</i> = 0.033). The number of pneumonia-free days during the study was considerably higher in the intervention group (<i>P</i> value of the log-rank test = 0.023).</p><p><strong>Conclusion: </strong>According to the results of this study, the HemoHIM herbal supplement had beneficial effects in preventing the occurrence of VAP and significantly reduced the incidence of pneumonia in the intervention group. Further comprehensive research is required to draw more accurate conclusions.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"12 2","pages":"58-63"},"PeriodicalIF":1.0,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the Prevalence of Contrast-associated Nephropathy and the Related Risk Factors in Patients Undergoing Elective Angioplasty. 研究择期血管成形术患者对比度相关性肾病的患病率及相关风险因素
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-31 eCollection Date: 2023-04-01 DOI: 10.4103/jrpp.jrpp_1_24
Mehrnoush Dianatkhah, Samira Poursaeid, Ehsan Shirvani, Shirinsadat Badri

Objective: Contrast-associated nephropathy (CAN) is a sudden decrease in kidney function following contrast media administration. Considering the importance of CAN in the patient's outcome and the high prevalence of this complication in cardiac catheterizing centers, this study was designed to investigate the prevalence and the related risk factors of CAN in patients undergoing angioplasty in Chamran Heart Hospital, Isfahan, Iran, from January 2022 to June 2022.

Methods: The inclusion criteria were adult patients above 18 admitted for elective percutaneous coronary intervention (PCI). Patient demographic information, underlying diseases and medications, dehydration state, type and amount of contrast media, and serum levels of blood urea nitrogen (BUN) and serum creatinine (SrCr) at 24 and 72 h after contrast injection were all recorded.

Findings: Out of 340, 128 patients developed CAN after PCI, giving an incidence of 37.64%. Adjusted analysis showed a significant relation between age over 65, the amount of contrast media administered, and the use of furosemide with the incidence of CAN. However, adjusted logistic regression analysis failed to show any significant relationship between the risk of CAN and the hydration status of the patients at 24 and 48 h after receiving contrast media as diagnosed by BUN/SrCr >20.

Conclusion: The prevalence of CAN in this study was higher than in other studies since this high-risk population was under risk factors such as arterial injection of contrast material and a higher amount of contrast material administration. In addition, advanced age, volume of contrast material, and previous or concurrent furosemide administration were associated with an increased risk of CAN.

目的:造影剂相关肾病(CAN)是指使用造影剂后肾功能突然下降。考虑到造影剂相关性肾病对患者预后的重要性以及该并发症在心导管中心的高发病率,本研究旨在调查 2022 年 1 月至 2022 年 6 月期间在伊朗伊斯法罕市 Chamran 心脏医院接受血管成形术的患者中造影剂相关性肾病的发病率及相关风险因素:纳入标准:接受择期经皮冠状动脉介入治疗(PCI)的 18 岁以上成年患者。患者的人口统计学信息、基础疾病和用药情况、脱水状态、造影剂的类型和用量以及注射造影剂后 24 小时和 72 小时的血清尿素氮(BUN)和血清肌酐(SrCr)水平均被记录在案:在 340 例患者中,有 128 例患者在 PCI 术后发生 CAN,发生率为 37.64%。调整后的分析表明,年龄超过 65 岁、造影剂用量和使用呋塞米与 CAN 的发生率有显著关系。然而,调整后的逻辑回归分析未能显示 CAN 风险与患者接受造影剂后 24 和 48 小时的水合状态(根据 BUN/SrCr >20 诊断)之间有任何显著关系:本研究中 CAN 的发病率高于其他研究,因为高危人群存在动脉注射造影剂和造影剂用量较多等风险因素。此外,高龄、造影剂用量、之前或同时使用呋塞米也与 CAN 风险增加有关。
{"title":"Investigating the Prevalence of Contrast-associated Nephropathy and the Related Risk Factors in Patients Undergoing Elective Angioplasty.","authors":"Mehrnoush Dianatkhah, Samira Poursaeid, Ehsan Shirvani, Shirinsadat Badri","doi":"10.4103/jrpp.jrpp_1_24","DOIUrl":"10.4103/jrpp.jrpp_1_24","url":null,"abstract":"<p><strong>Objective: </strong>Contrast-associated nephropathy (CAN) is a sudden decrease in kidney function following contrast media administration. Considering the importance of CAN in the patient's outcome and the high prevalence of this complication in cardiac catheterizing centers, this study was designed to investigate the prevalence and the related risk factors of CAN in patients undergoing angioplasty in Chamran Heart Hospital, Isfahan, Iran, from January 2022 to June 2022.</p><p><strong>Methods: </strong>The inclusion criteria were adult patients above 18 admitted for elective percutaneous coronary intervention (PCI). Patient demographic information, underlying diseases and medications, dehydration state, type and amount of contrast media, and serum levels of blood urea nitrogen (BUN) and serum creatinine (SrCr) at 24 and 72 h after contrast injection were all recorded.</p><p><strong>Findings: </strong>Out of 340, 128 patients developed CAN after PCI, giving an incidence of 37.64%. Adjusted analysis showed a significant relation between age over 65, the amount of contrast media administered, and the use of furosemide with the incidence of CAN. However, adjusted logistic regression analysis failed to show any significant relationship between the risk of CAN and the hydration status of the patients at 24 and 48 h after receiving contrast media as diagnosed by BUN/SrCr >20.</p><p><strong>Conclusion: </strong>The prevalence of CAN in this study was higher than in other studies since this high-risk population was under risk factors such as arterial injection of contrast material and a higher amount of contrast material administration. In addition, advanced age, volume of contrast material, and previous or concurrent furosemide administration were associated with an increased risk of CAN.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"12 2","pages":"64-67"},"PeriodicalIF":1.0,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Research in Pharmacy Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1